CD274 and Miyoshi myopathy: Immunotherapeutic approaches for MM have been long awaited because of the significantly impaired immune system due to the inhibition of normal plasma cells and the multiple mechanisms of immune evasion by MM cells, including the lack of unique targets that are highly expressed in MM cells but not normal cells, the enhanced expression of inhibitory ligands, such as programmed cell death ligand 1 (PDL1), and the recruitment of regulatory T cells (Tregs).